Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 12, 2016 - Issue 7
Submit an article Journal homepage
1,613
Views
12
CrossRef citations to date
0
Altmetric
Original Research

A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects

Roos AchterberghDepartment of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The NetherlandsCorrespondence[email protected]
,
Laureen A. LammersHospital Pharmacy, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Samuel van NieropDepartment of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Heinz-Josef KlümpenDepartment of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Maarten R. SoetersDepartment of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Ron A. A. MathôtHospital Pharmacy, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
&
Johannes A. RomijnDepartment of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
 show all
Pages 715-720 | Received 16 Sep 2015, Accepted 16 May 2016, Published online: 03 Jun 2016

References

  • Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250:186–200.
  • Wang Y-M, Ong SS, Chai SC, et al. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol. 2012;8:803–817.
  • Hernandez JP, Mota LC, Baldwin WS. Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr Pharmacogenomics Person Med. 2009;7:81–105.
  • Finn RD, Henderson CJ, Scott CL, et al. Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem J. 2009;417:43–54.
  • Ghose R, Omoluabi O, Gandhi A, et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 2011;89:57–64.
  • Puccinelli E, Gervasi PG, Longo V. Xenobiotic metabolizing cytochrome P450 in pig, a promising animal model. Curr Drug Metab. 2011;12:507–525.
  • Osabe M, Sugatani J, Fukuyama T, et al. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos. 2008;36:294–302.
  • Fleisher D, Li C, Zhou YP, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 1999;36:233–254.
  • Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62:1481–1502.
  • Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet. 2003;42:1071–1088.
  • Anderson KE, Kappas A. Dietary regulation of cytochrome P450. Annu Rev Nutr. 1991;11:141–167.
  • van der Meer RW, Hammer S, Lamb HJ, et al. Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men. J Clin Endocrinol Metab. 2008;93:2702–2708.
  • Turpault S, Brian W, Van HR, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68:928–935.
  • Zhang Y, Huo M, Zhou J, et al. An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306–314.
  • Bakker LE, van Schinkel LD, Guigas B, et al. A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young South Asian men but not in Caucasian men. Diabetes. 2014;63:248–258.
  • Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372–1379.
  • Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol. 2013;218:R25–36.
  • Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1:629–40.
  • Kolwankar D, Vuppalanchi R, Ethell B, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5:388–393.
  • Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450–mediated metabolism. Clin Pharmacol Ther. 2006;80:235–45.
  • Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187–216.
  • Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol. 1994;37:597–604.
  • McKee RF, MacGilchrist AJ, Garden OJ, et al. The anti-secretory effect and pharmacokinetics of omeprazole in chronic liver disease. Aliment Pharmacol Ther. 1988;2:429–437.
  • Kobuchi S, Fukushima K, Aoyama H, et al. Effects of obesity induced by high-fat diet on the pharmacokinetics of atazanavir in rats. Drug Metab Lett. 2013;7:39–46.
  • Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(Suppl 1):S5–10.
  • Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310–322.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.